Vaxcyte PCVX 深 沪
已收盘 12-19 16:00:00 美东时间
46.425
+2.715
+6.21%
华盛通- 最 高50.27
- 今 开43.81
- 成交量 172.11万股
- 最 低 42.40
- 昨 收 43.71
- 总市值 27.07亿
- 52周最高 93.77
- 市盈率 静 --
- 换手率 2.95%
- 52周最低 27.66
- 委 比 -80.91%
- 总股本 5831.38万
- 历史最高 121.055
- 量 比 1.32
- 振 幅 18.01%
- 历史最低 1.10
- 每 手 1
- 风险率 20.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CDC专家组支持扩大肺炎球菌疫苗接种年龄 辉瑞默沙东市场大扩容
美国疾病控制与预防中心(CDC)的免疫实践咨询委员会(ACIP)以14比1的投票结果推荐将肺炎球菌结合疫苗(PCV)的接种年龄建议降低至50岁及以上的成年人，这一决策可能显著扩大辉瑞(PFE.US)和默沙东(MRK.US)的疫苗市场。此前，CDC的建议是65岁以上的成年人和5岁以下的儿童接种肺炎球菌疫苗，同时建议某些免疫功能低下的群体接种。两家公司均请求CDC降低年龄建议至50岁以上的成年人。 这一建议得到了CDC主任曼迪·科恩的认可，她之前对肺炎球菌疫苗的指导主要集中在65岁以上的成年人和5岁以下的儿童。辉瑞和默沙东都希望这一变更能够增加他们的疫苗销售额。辉瑞的Prevnar是其最畅销的产品...
2024-10-24 15:15
B of A Securities Maintains Buy on Vaxcyte, Raises Price Target to $140
B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $101 to $140.
2024-09-04 19:34
Vaxcyte Starts $1 Billion Underwritten Public Offering
04:35 PM EDT, 09/03/2024 (MT Newswires) -- Vaxcyte (PCVX) said Tuesday it started a $1 billion underwritten public offering of common shares and pre-funded warrants. The company said it plans to give underwriters a 30-day option to buy up to an additional $150 million of common shares, including tho...
2024-09-04 04:35
Sector Update: Health Care Stocks Decline Late Afternoon
04:00 PM EDT, 09/03/2024 (MT Newswires) -- Health care stocks fell late Tuesday afternoon with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%. The iShares Biotechnology ETF (IBB) dropped 1.8%. In corporate news, TC BioPharm (TCBP) shares jumped 2...
2024-09-04 04:00
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM). Nikola shares dipped 10.4% to $7.28 on Monday. Here are some other stocks moving in tod...
2024-09-04 01:41
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Nasdaq Composite falling around 2% on Tuesday. Shares of Vaxcyte, Inc. (NASDAQ:PCVX) rose sharply during Tuesday's session after the company released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the compan...
2024-09-03 22:47
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Tuesday, Vaxcyte, Inc. (NASDAQ:PCVX) released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease. VAX-31 was well tolerated...
2024-09-03 21:40
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday
09:13 AM EDT, 09/03/2024 (MT Newswires) -- Health care stocks were leaning lower pre-bell Tuesday with the Health Care Select Sector SPDR Fund (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) recently declining by 0.8%. Vaxcyte (PCVX) shares rose past 31% after it announced plans to launch by...
2024-09-03 21:13
Wall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing Data
09:10 AM EDT, 09/03/2024 (MT Newswires) -- US stocks look set to open the shorted week lower in Tuesday's trading session following the Labor Day holiday, as investors await manufacturing data coming out later in the morning. The Dow Jones Industrial Average futures were down 0.48%, S&P 500 futures ...
2024-09-03 21:10
Vaxcyte Plans Phase 3 Trial for 31-Valent Pneumococcal Conjugate Vaccine Candidate After 'Positive' Phase 1/2 Study Results
08:31 AM EDT, 09/03/2024 (MT Newswires) -- Vaxcyte (PCVX) said Tuesday it plans to launch by mid-2025 a phase 3 study for VAX-31 following "positive" topline results from a phase 1/2 trial assessing the immunogenicity, safety, and tolerability of the 31-valent pneumococcal conjugate vaccine candidat...
2024-09-03 20:31
